ESMO Asia Virtual Congress 2020

Pembro-chemo improves PFS in Asian patients with inoperable/metastatic TNBC

Roshini Claire Anthony, 20210129180001

The addition of pembrolizumab to chemotherapy led to better progression-free survival (PFS) compared with chemotherapy only in Asian patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), according to a subgroup analysis of the KEYNOTE-355 study presented at ESMO Asia 2020.

Abemaciclib + fulvestrant survival benefit extends to Asians with HR+, HER- ABC

Pearl Toh, 20210112150000

Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.

Frontline sintilimab + bevacizumab biosimilar ups survival in advanced HCC

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

Pearl Toh, 20210108140010

Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.

Two-year maintenance olaparib could reduce ovarian cancer recurrence risk

Roshini Claire Anthony, 20210106180001

Two years of maintenance olaparib reduces recurrence risk in women with newly diagnosed advanced ovarian cancer with BRCA mutation (BRCAm), according to long-term results of the SOLO1* trial.

Anlotinib a new treatment alternative for thyroid cancer?

Audrey Abella, 20201130100000

Anlotinib demonstrated high survival benefit and treatment response rates in patients with locally advanced and metastatic radio-iodine-refractory differentiated thyroid carcinoma (RAIR-DTC), a phase II study from China has shown.

Subgroup findings boost ribociclib-letrozole potential in Asians with HR+, HER2– advanced breast cancer

Audrey Abella, 20201126100000

In a subgroup analysis of the phase IIIb CompLEEment-1 trial, ribociclib plus letrozole showed a manageable safety profile in Asian patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC).